CN115427037A - 达立克生(daridorexant)的医药用途 - Google Patents

达立克生(daridorexant)的医药用途 Download PDF

Info

Publication number
CN115427037A
CN115427037A CN202180028992.7A CN202180028992A CN115427037A CN 115427037 A CN115427037 A CN 115427037A CN 202180028992 A CN202180028992 A CN 202180028992A CN 115427037 A CN115427037 A CN 115427037A
Authority
CN
China
Prior art keywords
sleep
daytime
insomnia
idsiq
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180028992.7A
Other languages
English (en)
Chinese (zh)
Inventor
盖伊·布朗斯坦
斯科特·帕因
达尔马·塞博克-金特
塞德里克·瓦利恩特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actelion Pharmaceuticals Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of CN115427037A publication Critical patent/CN115427037A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202180028992.7A 2020-04-19 2021-04-16 达立克生(daridorexant)的医药用途 Pending CN115427037A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2020060940 2020-04-19
EPPCT/EP2020/060940 2020-04-19
PCT/EP2021/059943 WO2021213923A1 (en) 2020-04-19 2021-04-16 Medical use of daridorexant

Publications (1)

Publication Number Publication Date
CN115427037A true CN115427037A (zh) 2022-12-02

Family

ID=75478068

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180028992.7A Pending CN115427037A (zh) 2020-04-19 2021-04-16 达立克生(daridorexant)的医药用途

Country Status (14)

Country Link
US (1) US20230134935A1 (https=)
EP (1) EP4138822A1 (https=)
JP (1) JP7822954B2 (https=)
KR (1) KR20230004670A (https=)
CN (1) CN115427037A (https=)
AU (1) AU2021260018A1 (https=)
BR (1) BR112022020924A2 (https=)
CA (1) CA3175369A1 (https=)
CL (1) CL2022002855A1 (https=)
IL (1) IL297234A (https=)
MX (1) MX2022011179A (https=)
PH (1) PH12022552763A1 (https=)
TW (1) TW202200133A (https=)
WO (1) WO2021213923A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115925699B (zh) * 2022-02-25 2023-10-03 南京知和医药科技有限公司 具有镇痛活性的稠环化合物及其制备方法与用途
WO2024019978A2 (en) * 2022-07-19 2024-01-25 Rutgers, The State University Of New Jersey Therapeutic combinations and methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013502447A (ja) * 2009-08-24 2013-01-24 グラクソ グループ リミテッド 睡眠障害の治療のためのオレキシン受容体アンタゴニストとしての５−メチル−ピペリジン誘導体
ES2617863T3 (es) 2012-06-04 2017-06-20 Actelion Pharmaceuticals Ltd. Derivados de bencimidazol-prolina
MY179862A (en) 2013-12-03 2020-11-18 Idorsia Pharmaceuticals Ltd Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
SI3077391T1 (sl) 2013-12-04 2018-11-30 Idorsia Pharmaceuticals Ltd Uporaba benzimidazol-prolinskih derivatov
ES2843952T3 (es) 2014-10-23 2021-07-21 Eisai R&D Man Co Ltd Composiciones para tratar el insomnio
LT3619199T (lt) 2017-05-03 2021-09-27 Idorsia Pharmaceuticals Ltd 2-([1,2,3]triazol-2-il)-benzenkarboksirūgšties darinių gamyba

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DAUVILLIERS, YVES等: "Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder", 《ANNALS OF NEUROLOGY》, vol. 87, no. 3, 17 January 2020 (2020-01-17), pages 347 - 356 *

Also Published As

Publication number Publication date
CA3175369A1 (en) 2021-10-28
TW202200133A (zh) 2022-01-01
JP2023521492A (ja) 2023-05-24
BR112022020924A2 (pt) 2023-02-14
AU2021260018A1 (en) 2022-12-22
MX2022011179A (es) 2022-10-07
WO2021213923A1 (en) 2021-10-28
KR20230004670A (ko) 2023-01-06
JP7822954B2 (ja) 2026-03-03
IL297234A (en) 2022-12-01
US20230134935A1 (en) 2023-05-04
EP4138822A1 (en) 2023-03-01
CL2022002855A1 (es) 2023-06-02
PH12022552763A1 (en) 2024-03-25

Similar Documents

Publication Publication Date Title
RU2281771C2 (ru) Использование декстрометорфана и ингибитора оксидазы для отучения пациентов от наркотиков и антидепрессантов
US20060122127A1 (en) Methods for reducing the side effects associated with mirtzapine treatment
US20060252761A1 (en) Augmentation of extinction via administration of sub-antimicrobial doses of D-cycloserine
KR20180031721A (ko) 가복사돌로 발달장애들을 치료하는 방법들
US12485100B2 (en) Treatment of menstrual cycle-induced symptoms
Woodward Sleep in older people
KR20250005178A (ko) 수면 장애의 치료에 사용하기 위한 5-meo-dmt
JP7822954B2 (ja) ダリドレキサントの医学的用途
EA051128B1 (ru) Медицинское применение даридорексанта
Collins et al. Pediatric cancer pain
Morin et al. Insomnia in adults
Brown et al. Psychiatric disorders
HK40075517A (en) Treatment of menstrual cycle-induced symptoms
HK40075517B (en) Treatment of menstrual cycle-induced symptoms
Gupta et al. Calming contest-a battle between nitrous oxide and oral sedation-who wins in paediatric minds
Rutkofsky et al. Gabapentin for Post-Hospitalization Alcohol Relapse Prevention; Should Gabapentin Be Considered for FDA Approval in the Treatment of Alcohol Use Disorder?: A Case Presentation and Literature Review
Fleming 3.3 Sleep Difficulties and Disorders in Older Adults, and Their Management
HK40112834A (zh) 用於痴呆和神经变性病况中的激越、精神病和认知衰退的环苯扎林治疗
EA049139B1 (ru) Лечение симптомов, вызванных менструальным циклом
REINEMER APPROVED BY THE GRADUATE COUNCIL, COLLEGE^ PF—DENTISTRY:(signed) _ f Assistant Dean of Research and Advanced Education APPROVED BY THE GRADUATE COUNCIL
Shabangu The efficacy of a homoeopathic complex (Nux moschata D6, Phosphoricum acidum D30, Helleborus niger D6, Opium D30) in management of excessive daytime sleepiness
Moch Sleepless in South Africa: insomnia is not just a night-time problem
BRALEY et al. Sleeptions among persons with comorbidmultiple sclero-condi
Brahm et al. Autism spectrum disorders and sleep disturbances in a pediatric patient
Neubauer et al. Pharmacological Management of Insomnia

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination